Scientific Publications



Overexpression of α1 chain of type XI collagen (COL11A1) aids in the diagnosis of invasive carcinoma in endoscopically removed malignant colorectal polyps. Zhang D. et al. Pathology Research and Practice 2016; 212:545-548

Collagen Type XI Alpha 1 Expression in Intraductal Papillomas Predicts Malignant Recurrence. Freire J. et al. BioMed Research International 2015; 2015:812027

COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression.. Vázquez-Villa F. et al. Tumor Biology 2015; 36(4):2213-22

Overexpression of proCOL11A1 as a stromal marker of breast cancer. Fuentes-Martínez N. et al. Histol Histopathol. 2015; 30(1):87-93

Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. Galván JA. et al. BMC Cancer 2014; 14:867

Collagen, type XI, alpha 1: an accurate marker for differential diagnosis of breast carcinoma invasiveness in core needle biopsies. Freire J. et al. Pathology Research and Practice 2014; 210(12): 879-884

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Cheon DJ. et al. Clinical Cancer Research 2014; 20(3):711-23

Overexpression of COL11A1 by Cancer-Associated Fibroblasts: Clinical Relevance of a Stromal Marker in Pancreatic Cancer. García-Pravia C. et al. PLoS ONE 2013; 8(10)1-13

Characterization of a novel mouse monoclonal antibody, clone 1E8.33, highly specific for human procollagen 11A1, a tumor-associated stromal component. García-Ocaña M. et al. International Journal of Oncology 2012; 40(5):1447-1454


Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Martínez-Torrecuadrada JM. et al. Clinical Cancer Research 2005; 11(17):6280-90

Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Gómez-Román J. et al. Clinical Cancer Research 2005; 11:459-465



Plexin B1 is downregulated in renal cell carcinomas and modulates cell growth. Gómez-Román J. et al. Translational Research 2008; 151(3):134-140



Isolation and partial characterization of nigrin b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of Sambucus nigra L. Girbés T. et al. Plant Molecular Biology 1993; 22(6):1181-1186

Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice. Gayoso MJ. et al. Toxicology and applied pharmacology 2005; 207(2):138-46

Targeting a marker of the tumor neovasculature using a novel anti-human CD105 immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b. Muñoz R. et al. Cancer Letters 2007; 256(1):73–80

Occurrence and new procedure of preparation of nigrin, an antiribosomal lectin present in elderberry bark. Ferreras JM. et al. Food Research International 2011; 44(9):2798–2805

Use of ribosome-inactivating proteins from sambucus for the construction of immunotoxins and conjugates for cancer therapy.. Ferreras JM. et al. Toxins (Basel). 2011; 3(5):420-41

In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumors. Muñoz R. et al. Cancer Immunology Immunotherapy 2013; 62(3):541-551



Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. Sasse F. et al. The Journal of Antibiotics 2000; 53(9):879-885

Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.Kaur G. et al. The Biochemical Journal. 2006; 396(2):235-242

Polymeric tubulysin-peptide nanoparticles with potent antitumor activity.Schluep T. et al. Clinical Cancer Research 2009; 15(1):181-189

In Vivo Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates. Reddy J. et al. Molecular Pharmaceutics 2009; 6(5)1518-1525


By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.